Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage

American Journal of Hematology

Volumn 69, Issue 3, 2002, Pages 219-222

  Gerotziafas, Grigoris T ^a   Zervas, Costas ^a   Gavrielidis, George ^a   Tokmaktsis, Aggelos ^b   Hatjiharissi, Evdoxia ^a   Papaioannou, Mary ^a   Lazaridou, Anna ^a   Constantinou, Nikos ^a   Samama, Meyer Michel ^b   Christakis, John ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b HÔTEL DIEU   (France)

Author keywords

Hemorrhage; NovoSeven; Recombinant factor VIIa; Thrombocytopenia

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FLUDARABINE; MERCAPTOPURINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B LYMPHOBLAST; BLEEDING; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

AGED; CRITICAL ILLNESS; FACTOR VIIA; FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, PRE-B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; WALDENSTROM MACROGLOBULINEMIA;

EID: 0036177902     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10056     Document Type: Article

References (22)

1. Alloimmunization following platelet transfusion: The absence of a dose-response relationship
2. Prevention and management of platelet transfusion refractoriness
3. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors
4. Recombinant activated factor VII as a universal haemostatic agent
5. Treatment of patients with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
6. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
7. Recombinant activated factor VII (Novo-Seven) treatment of platelet-related bleeding disorders
8. Recombinant factor VIIa in severe uremic bleeding
9. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
10. Autoimmune thrombocytopenia in Waldenström macroglobulinaemia
11. Autoimmune thrombocytopenia: A complication of fludarabine therapy in lymphoproliferative disorders
12. Efficacy of platelet transfusions in immune thrombocytopenia
13. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII
14. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: Results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors
15. Dosing and monitoring NovoSeven treatment
16. Recombinant factor VIIa for bleeding in refractory thrombocytopenia
17. The tissue factor pathway: How it has become a "prima ballerina"
18. Platelet activity of high dose factor VIIa is independent of tissue factor
19. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high dose activated FVII
20. Studies on the activation of factor VII bound to tissue factor
21. Levels of prothrombin activation peptide F1 + 2 in patients with bleeding tendency
22. Clinical experience with activated factor VII: Focus on safety aspects